Business
VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
LEIDEN, Netherlands, September 16, 2025--VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational blood coagulation treatment VMX-C001.
About this update from Csl Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/b4a4aa5541b6a572b03f70f24ad6d2c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LNhAihZoc6PR2AOxnxEpzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b4a4aa5541b6a572b03f70f24ad6d2c7","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_S7FK1JVL4dYxFipO6_tcw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/b4a4aa5541b6a572b03f70f24ad6d2c7","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities","length":111,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"VarmX shareholders to receive initial $117m upfront and further potential milestone payments up to $2.1bn","length":105,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Transformational step for VarmX, well positioned to bring VMX-C001 to patients","length":78,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Exclusive option agreement for CSL to acquire all issued and outstanding shares of the company, dependent on Phase 3 data","length":121,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":415,"olType":false},{"type":"text","content":"LEIDEN, Netherlands, September 16, 2025--(BUSINESS WIRE)--VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has entered into a strategic collaboration with global biotechnology leader, CSL (ASX:CSL), to support the development of its lead asset, VMX-C001. VMX-C001 is a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs. CSL has also entered into an exclusive option agreement with VarmX shareholders to acquire all issued and outstanding shares of the company.","length":681,"tagName":"p"},{"type":"text","content":"Under the terms of the strategic collaboration agreement, CSL will ful...